Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »
HomeLetteratura
Archivio

Objective: The purpose of our study was to evaluate the contribution of an automated drug dispensing system in securing cancer chemotherapy production process at the pharmacy of the National Institute of Oncology in Rabat. Methods: The failure modes and effects analysis method was applied to the chemotherapy production process in two phases:

Journal of Oncology Pharmacy Practice; https://doi.org/10.1177/1078155220941060. /  Ouedraogo JM, El Baraka S, Adade CA, et al.

Objective: To propose an updated definition of Pharmaceutical Care based on the Capacity-Motivation-Opportunity (CMO) model and on the key elements and optimal activities for its development that guarantee the highest levels of quality and excellence in this professional activity. Method: The consensus was developed by a working group composed of members of the

Farm Hosp 2020:44(4):158-162. /  Morillo-Verdugo R, Calleja-Hernández MA, Robustillo-Cortés M, et al.

Introduction: The primary objective of this study was to describe the incorporation of the flipped classroom model and use of real-life oncology patients to facilitate student learning of oral oncolytic best safety practices and patient counseling. The secondary objective was to assess the impact of the flipped classroom learning activity

Journal of Clinical Pharmacy 20020; https://doi.org/10.1177/1078155220940395. /  Duffy AP, Henshaw A, Trovato JA, et al.

Objectives: To evaluate clinical and financial impact of pharmacist interventions in an ambulatory adult hematology-oncology department. Methods: All cancer patients receiving a first injectable immuno- and/or chemotherapy regimen were included in this prospective study over a one-year period. The clinical impact of pharmacist interventions made by two clinical pharmacists was rated using the

de Grégori J, Pistre P, Boutet M, et al.

Objective: . To collate the evidence on the accuracy parameters of all available diagnostic methods for detecting SARS-CoV-2. Methods: . A systematic review with meta-analysis was performed. Searches were conducted in Pubmed and Scopus (April 2020). Studies reporting data on sensitivity or specificity of diagnostic tests for COVID-19 using any human biological sample

Am J Infect Control 2020;S0196-6553(20)30693-3. /  Böger B, Fachi MM, O Vilhena R,et al.

The outbreak of SARS-CoV-2-associated pneumonia, a disease called COVID-19, has caused a pandemic worldwide. To investigate the immune responses after infection of SARS-CoV-2 in non-critical patients may help to better understand the disease progression. We collected 334 confirmed COVID-19 cases including 212 still in hospital with nucleic acid test positive

Clinical Immunology 2020: https://doi.org/10.1016/j.clim.2020.108524. /  Lin L, Luo S, Qin R,et al.

The anti-CD19 chimeric antigen receptor (CAR)-T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We correlated tisagenlecleucel cellular kinetics with clinical/product parameters in 111 patients treated in JULIET. Tisagenlecleucel persistence in responders and nonresponders, respectively, was

Awasthi R, Pacaud L, Waldron E, et al.

Ribociclib (LEE011, Kisqali ®) is a highly selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6 (CDK4/6), which has been approved for the treatment of advanced or metastatic breast cancer. A human ADME study was conducted in healthy male volunteers following a single oral dose of 600 mg [14C]‐ribociclib. Mass

J Oncol Pharm Pract. 2020;26(5):1172-1179. /  James AD, Schiller H, Marvalin C, et al.

Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19+ B cell malignancies, multiple clinical trials of CAR T cell therapy directed to

Clin Invest 2020(4):1586-1594. /  Frigault MJ, Maus MV.

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. Methods: We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18

N Engl J Med 2020 Jul 14. Online ahead of print. /  Jackson LA, Anderson EJ, Rouphael NJ, et al.